The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on September 16, 2025 for Ravi Agrawal, trustee ....
AJANTPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Ravi Agrawal, trustee of the Ravi Agrawal Trust and a promoter of Ajanta Pharma, has disclosed both creation and release of pledges on his shares. On 9 September 2025, he released a pledge on 1,15,000 shares (0.09% of share capital) with Infina Finance Private Limited. Subsequently, on 11 September 2025, he created new pledges of 2,00,000 shares (0.16%) with HSBC Investdirect and 45,000 shares (0.04%) with Bajaj Finance Limited. The reasons cited for both creation and release is business financing / re-financing. After these transactions, the total encumbered shares held by the Ravi Agrawal Trust stand at 60,07,642 shares (4.81% of share capital), a net increase of 1,30,000 shares in pledged holdings.
The net pledge creation of 1.30 lakh shares is marginal and part of routine re-financing activity by the promoter, not an indication of distress or stake sale. Shareholders are unlikely to see any material impact on the stock from this disclosure.